美国指南变迁期间妊娠期糖尿病药物处方模式的变化:横断面研究
该横断面研究基于美国商业保险数据(2015年末至2018年),分析37 762名GDM孕妇中10 407名(28%)接受药物治疗者的处方模式。结果显示二甲双胍使用从17%升至29%,胰岛素从26%升至44%,格列本脲从58%降至27%;到2018年胰岛素成为最常用药物,二甲双胍处方可能性较2015末/16年高9%,格列本脲低45%。
要点
- GDM药物治疗中胰岛素和二甲双胍已取代格列本脲成为最常用选择
- 二甲双胍治疗者中20%发生治疗调整,胰岛素仅2%,格列本脲8%
- 需进一步评估二甲双胍与胰岛素在GDM中的相对有效性和安全性
核心结论
- 在美国指南演变期间,胰岛素和二甲双胍已取代格列本脲成为GDM最常用药物治疗。
研究设计与样本
- 横断面研究,数据来自MarketScan美国商业保险受益人(2015年末至2018年)。
- 纳入37 762名GDM孕妇,分析其中10 407名(28%)接受药物治疗者,均为单胎妊娠、15-51岁。
主要发现
- 药物治疗分布:二甲双胍21%(n=2147),格列本脲48%(n=4984),胰岛素31%(n=3276)。
- 2015年末至2018年,二甲双胍使用从17%增至29%,胰岛素从26%增至44%,格列本脲从58%降至27%。
- 到2018年胰岛素为最常见药物;二甲双胍处方可能性较2015末/16年高9%,格列本脲低45%。
- 治疗调整发生率:二甲双胍20%,格列本脲8%,胰岛素2%。
临床怎么用
- 临床处方GDM药物时可参考胰岛素和二甲双胍作为主要选择,格列本脲使用应减少。
- 使用二甲双胍者需注意较高的治疗调整率(20%),必要时及时调整方案。
局限性
- 研究基于美国商业保险人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To define patterns of prescription and factors associated with choice of pharmacotherapy for gestational diabetes mellitus (GDM), namely metformin, glyburide and insulin, during a period of evolving professional guidelines. DESING: Cross-sectional study. SETTING: US commercial insurance beneficiaries from Market-Scan (late 2015 to 2018). STUDY DESIGN: We included women with GDM, singleton gestations, 15-51 years of age on pharmacotherapy. The exposure was pharmacy claims for metformin, glyburide and insulin. MAIN OUTCOMES: Pharmacotherapy for GDM with either oral agent, metformin or glyburide, compared with insulin as the reference, and secondarily, consequent treatment modification (addition and/or change) to metformin, glyburide or insulin. RESULTS: Among 37 762 women with GDM, we analysed data from 10 407 (28%) with pharmacotherapy, 21% with metformin (n = 2147), 48% with glyburide (n = 4984) and 31% with insulin (n = 3276). From late 2015 to 2018, metformin use increased from 17 to 29%, as did insulin use from 26 to 44%, whereas glyburide use decreased from 58 to 27%. By 2018, insulin was the most common pharmacotherapy for GDM; metformin was more likely to be prescribed by 9% compared with late 2015/16, but glyburide was less likely by 45%. Treatment modification occurred in 20% of women prescribed metformin compared with 2% with insulin and 8% with glyburide. CONCLUSIONS: Insulin followed by metformin has replaced glyburide as the most common pharmacotherapy for GDM among a privately insured US population during a time of evolving professional guidelines. Further evaluation of the relative effectiveness and safety of metformin compared with insulin is needed. TWEETABLE ABSTRACT: Insulin followed by metformin has replaced glyburide as the most common pharmacotherapy for gestational diabetes mellitus in the USA.
引用
- Venkatesh KK, Chiang CW, Castillo WC, et al. Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study. BJOG. 2021. PMID: 34605130. doi:10.1111/1471-0528.16960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。